Anti-tumor activity of immune cells can be restored

December 10, 2013, VIB (the Flanders Institute for Biotechnology)

The Leuven-based VIB researchers have revealed a mechanism that explains why the anti-tumor activity of specific immune cells called macrophages is suppressed during tumor growth. They have also demonstrated that blocking the protein Nrp1 can restore this anti-tumor immune response. This is a first. Nrp1 may provide an important hub for the development of new therapies against cancer.

Max Mazzone: "For many years the biological processes which lead to the coordinated navigation of and nerves have been studied. The first observations come, in fact, from the Belgian anatomist Andreas Vesalius. So we were surprised to discover that immune cells follow the same

signals of blood vessels and nerves to position themselves within the cell and, in doing so, contribute to . By blocking these signals, we can once again turn the against the tumor."

Macrophages and cancer

Macrophages are important cells within the immune system. Among other things, they are responsible for cleaning up pathogens, such as bacteria and viruses. Macrophages, however, also appear to play an important and complex role in the occurrence and metastatization of cancer.

Macrophages that migrate to the tumor are called tumor-associated or TAMs for short. Extensive infiltration of TAMs into the tumor is often correlated with a poor prognosis in various cancers. These TAMs suppress the immune system and stimulate blood vessel formation thereby stimulating the growth of the tumor. On the other hand, there are also studies that show just the opposite effect, reaching the conclusion that TAMs have an anti-tumor effect.

The opposing functions of TAMs in the development of tumors arise the question whether there are specific factors within the micro-environment of the tumor which dictate the phenotype of these TAMs.

Neuropilin-1 (Nrp1)

Andrea Casazza and his colleagues, under the direction of Massimiliano Mazzone, studied the mechanism that is responsible for the opposing phenotypes of TAMs. Their study showed that the protein neuropilin-1 (Nrp1) is crucial for the localization of TAMs inside hypoxic tumor regions, which strengthens the pro-tumoral characteristics of TAMs.

Consequently, they discovered that by blocking Nrp1, macrophages were no longer able to migrate inside hypoxic regions in the tumor. It is in this way that the anti-tumoral activity of the macrophages is restored. Less suppression of the immune response and less in the tumor leads to less tumor growth.

Impact of this research

This pre-clinical study from Professor Mazzone and his colleagues reveals a new molecular axis that may offer interesting therapeutic opportunities for the treatment of pancreatic cancer, breast cancer and lung cancer, among others. The goal of a therapy like this is to restore the anti-tumor phenotype of

macrophages. After all, macrophages are cells that are normally part of our immune systems.

Furthermore, these results also have an important prognostic value—the positioning of macrophages in hypoxic tumor regions would be an indication of a poor prognosis, while the localization of macrophages in normoxic regions of the tumor could predict a better disease outcome.

Explore further: Depletion of 'traitor' immune cells slows cancer growth in mice

More information: This research appears in the journal Cancer Cell: Casazza et al., Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores anti-tumor immunity).

Related Stories

Depletion of 'traitor' immune cells slows cancer growth in mice

September 16, 2013
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy ...

Key driver of metastasis identified

October 31, 2011
Scientists at Dalhousie University in Nova Scotia have identified a key mechanism of metastasis that could lead to blocking tumor growth if their findings are confirmed.

Using CD47's protection to deliver anti-cancer drugs directly to tumor cells

October 9, 2012
(Medical Xpress)—For most of their natural lives, red blood cells hide safely under the radar of the body's immune system, thanks to a cloak of "don't eat me" protein called CD47. Ching-An Peng of Michigan Technological ...

Recommended for you

New therapeutic gel shows promise against cancerous tumors

February 21, 2018
Scientists at the UNC School of Medicine and NC State have created an injectable gel-like scaffold that can hold combination chemo-immunotherapeutic drugs and deliver them locally to tumors in a sequential manner. The results ...

Five novel genetic changes linked to pancreatic cancer risk

February 21, 2018
In what is believed to be the largest pancreatic cancer genome-wide association study to date, researchers at the Johns Hopkins Kimmel Cancer Center and the National Cancer Institute, and collaborators from over 80 other ...

Similarities found in cancer initiation in kidney, liver, stomach, pancreas

February 21, 2018
Recent research at Washington University School of Medicine in St. Louis demonstrated that mature cells in the stomach sometimes revert back to behaving like rapidly dividing stem cells. Now, the researchers have found that ...

Kinase inhibitor larotrectinib shows durable anti-tumor abilities

February 21, 2018
Three simultaneous safety and efficacy studies of the drug larotrectinib reported an overall response rate of 75 percent for patients ages four months to 76 years with 17 different cancer diagnoses. All patients had tumors ...

Research could change how doctors treat leukemia and other cancers fed by fat

February 21, 2018
Obesity and cancer risk have a mysterious relationship, with obesity increasing the risk for 13 types of cancer. For some cancers—including pediatric cancers—obesity affects survival rates, which are lower for people ...

New technique predicts gene resistance to cancer treatments

February 21, 2018
Yale School of Public Health researchers have developed a new method to predict likely resistance paths to cancer therapeutics, and a methodology to apply it to one of the most frequent cancer-causing genes.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.